DMTTF - Small Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0542
-0.0018 (-3.21%)
At close: 03:25PM EDT
Stock chart is not supported by your current browser
Previous Close0.0560
Open0.0598
BidN/A x N/A
AskN/A x N/A
Day's Range0.0500 - 0.0606
52 Week Range0.0465 - 0.3328
Volume403,519
Avg. Volume103,459
Market Cap17.936M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Small Pharma Announces Significant Developments In Intellectual Property Portfolio

    5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictionsLONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property ("IP") portfolio, demonstrating significant progress already made by the Company in 2023. Small

  • GlobeNewswire

    Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

    Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive DisorderLONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that Dr. Carol Routledge, Chief Medical and Scient

  • GlobeNewswire

    Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026

    Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months Aggregated Remission Rates Aggregated Remission Rates LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive six-month data from the Company’

  • GlobeNewswire

    Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

    LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will host a virtual Key Opinion Leader roundtable with Jerry Rosenbaum, MD, Professor of Psychiatry at Harvard Medical School, and David Erritzoe, MD, PhD, Imperial College London on Wednesday, March 15, 2023 at 2:00 p.m. EDT. Dr. Carol Routl

  • GlobeNewswire

    Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

    Small Pharma Inc. Phase IIa Trial Data Small Pharma Inc. Phase IIa Trial Data -Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health

  • GlobeNewswire

    Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

    Company will also host a cocktail reception on Tuesday, March 7LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in Cowen’s 43rd Annual Health Care Conference, taking pl

  • GlobeNewswire

    First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

    SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today confirms that the first subject has been dosed in a Phase I study evaluating SPL028,

  • GlobeNewswire

    Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

    New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectua

  • Baystreet

    Stocks in play: Small Pharma Inc.

    Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment ...

  • GlobeNewswire

    Small Pharma Reports Fiscal Third Quarter 2023 Highlights

    Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2

  • GlobeNewswire

    Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

    First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant -7.4 point difference between SPL026 (21.5mg) and placebo at two-weeks post-dose as measured by MADRS change from baseline (p=0.02) Antidepressant effect of SPL026, with supportive therapy, demonstrated a rapid onset at one-week post-dose with a statistically significant difference in MADRS of

  • GlobeNewswire

    Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

    LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will release top-line data from its Phase IIa trial of SPL026 in Major Depressive Disorder (“MDD”) prior to market-open tomorrow on Wednesday, January 25, 2023. The Small Pharma management team will host a conference call at 8:30am EST / 1:30p

  • GlobeNewswire

    First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

    Study will compare the profile of intramuscular versus intravenous SPL026 administrationLONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the first patient has been dosed in its Phase I study comparing the profiles of intramuscular (“IM”) and intravenous (“IV”) , the Company’s proprietary formulati

  • GlobeNewswire

    Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

    Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline candidates LONDON, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that the last patient has completed its final visit in t

  • GlobeNewswire

    First Patient Dosed in Small Pharma’s Drug Interaction Study

    Open-label study will assess the interaction between SSRI antidepressants and SPL026LONDON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the first patient has been dosed in the Company’s Phase Ib drug interaction study. The study aims to assess the interaction between selective serotonin reuptake inhi

  • GlobeNewswire

    Small Pharma To Support University College London Research Project on Neuroplasticity

    Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-beingLONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it will provide its drug candidate SPL026, an intravenous formulation of the psyche

  • GlobeNewswire

    Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium

    LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in an industry panel and host one-on-one investor meetings at the virtual Canaccord Genuity Symposium on New Paradigms and

  • GlobeNewswire

    Small Pharma to Participate in November Investor and Healthcare Conferences

    LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce its participation in the following upcoming conferences in November. Jefferies London Healthcare Conference, November 15-17 George Tziras, Chief Executive Officer of the Company, will participate in a fireside chat on November 16, 2022 at 4:25 p.

  • GlobeNewswire

    Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028

    SPL028 is the Company’s injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration of SPL028 LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received appr

  • GlobeNewswire

    Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

    Brings total to twelve granted patents across the Company’s full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of October 18, 2022, it has been granted patent no. 11,471,417 by the United States Patent Office. This United States patent provides protection for a therapeutic composi

  • GlobeNewswire

    Small Pharma Reports Fiscal Second Quarter 2023 Highlights

    Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion of 12-week follow up anticipated by year end with data shortly thereafter SSRI drug interaction study initiated MHRA approval for new SPL026 trial LONDON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapi

  • GlobeNewswire

    Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

    Dosing for primary endpoint now completeLONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of its intravenous (“IV”) formulation of N, N-dimethyltryptamine (“DMT”) candidate, SPL026, with psychotherapy for the treatment of Major Depressiv

  • GlobeNewswire

    Small Pharma Enters Into Automatic Share Purchase Plan

    LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announced that it has entered into an automatic share purchase plan (the “ASPP”) with Eight Capital (the “Broker”) in order to facilitate repurchases of the Company's common shares (the “Shares”) under its previously announced normal course issuer bid (the “NCIB

  • GlobeNewswire

    Small Pharma to Participate in Upcoming September Investor Conferences

    LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in upcoming investor conferences this September. Details of the sessions are as follows: H.C. Wainwright 24th Annual Global Investment

  • GlobeNewswire

    Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

    LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that the TSX Venture Exchange (the “TSXV”) has accepted the Company’s application for its normal course issuer bid (the “NCIB”) for up to five million common shares (“Shares”) in the capital of the Company, representing 1.55% of the issued and outstandi